Brainomix

Brainomix operates at the intersection of medical imaging AI, clinical decision support, and precision medicine. Its core differentiation is breadth across two high-value pathways: Brainomix 360 Stroke interprets CT, CT angiography, CT perfusion, and MRI data for acute treatment and transfer decisions, while e-Lung quantifies lung features on CT to support detection, monitoring, and prognosis in interstitial and progressive pulmonary fibrosis. The company also sells imaging-biomarker and clinical-trial analytics capabilities to life-sciences organizations, extending its role beyond hospital workflow software. Brainomix reports deployments across more than 350 hospitals worldwide, including more than 70 NHS hospitals and all 25 sites in the West Virginia University Health System. The company cites a 100% increase in thrombectomy rates in a large real-world evaluation, giving its stroke platform an outcomes-oriented commercial narrative rather than a purely technical one. Its FDA clearance for e-Lung and use in Phase 3 studies strengthen regulatory and clinical credibility. The clearest competitive distinction is the combination of stroke operations, pulmonary-fibrosis biomarkers, and pharmaceutical trial support within one Oxford-founded platform.

Brainomix shows a progression from an Oxford spinout founded in 2010 into a multi-indication medical-imaging company. Early financing included a 2014 Series A, a 2016 Series B, and a 2018 venture round led by Parkwalk Advisors. The company then raised $21.3 million in its 2021 Series B and $18.2 million in a 2025 Series C, followed by a further $6.5 million Series C round announced on Feb 24, 2026. Including grants and earlier rounds, total funding reaches $60.2 million. Product expansion has been the main operating inflection point. Brainomix 360 Stroke moved from national NHS deployment to U.S. health-system expansion, including a 25-site rollout in March 2026. In parallel, e-Lung progressed from an FDA-cleared product to a technology used as a co-primary endpoint in a Phase 3 trial and in the PROGRESS-PPF study with Boehringer Ingelheim. The company had more than 75 employees by March 2025 and was actively hiring, indicating continued commercial and clinical scaling. Partnerships with Medtronic, 3DR Labs, Boehringer Ingelheim, West Virginia University Health System, and Endeavor BioMedicines broaden distribution and validation. The trajectory is therefore shifting from single-product stroke software toward a diversified imaging-biomarker platform.